[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100550516":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":25,"centralContacts":29,"locations":35,"responsibleParty":80,"collaborators":82,"id":86,"slug":87,"hasResults":88,"nctId":89,"briefTitle":90,"officialTitle":90,"acronym":91,"eligibilityCriteria":92,"healthyVolunteers":93,"sex":94,"minAge":95,"maxAge":18,"enrollmentInfo":96,"targetDuration":18,"studyType":99,"phases":100,"briefSummary":102,"conditions":103,"keywords":18,"overallStatus":56,"whyStopped":18,"lastUpdateSubmitDate":105,"lastUpdatePostDateStruct":106,"startDateStruct":109,"completionDateStruct":111,"leadSponsor":113,"locationsCount":114},{"fullName":5,"class":6},"University of Florida","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Experimental: Immediate panel-based pharmacogenetic genotyping","EXPERIMENTAL","Subjects assigned to the immediate pharmacogenetic genotyping group will be tested and have their results both entered into their electronic health record as well as provided to them within 2-4 weeks from randomization.",[13],"Diagnostic Test: Panel-based pharmacogenetic genotyping",{"label":15,"type":16,"description":17,"interventionNames":18},"Delayed panel-based pharmacogenetic genotyping","NO_INTERVENTION","Subjects assigned to delayed panel-based pharmacogenetic genotyping will not be tested until after their participation in the study has ended (6 months after enrollment).",null,[20],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":18},"DIAGNOSTIC_TEST","Panel-based pharmacogenetic genotyping","After consent and randomization into the immediate PGx testing, participants' results will (10-14 days after randomization) go into their EHR and be returned via a laminated results card",[9],[26],{"name":27,"affiliation":5,"role":28},"Julio D Duarte, Pharm.D., Ph.D.","PRINCIPAL_INVESTIGATOR",[30],{"name":31,"role":32,"phone":33,"phoneExt":18,"email":34},"Erica N Elwood, MHA","CONTACT","3522736007","erica.elwood@cop.ufl.edu",[36,54,71],{"facility":37,"status":38,"city":39,"state":40,"zip":41,"country":42,"countryCode":43,"cosmosGeoPoint":44,"geoPoint":49,"contacts":50},"UF Health Emergency Department","NOT_YET_RECRUITING","Gainesville","Florida","32610","United States","US",{"type":45,"coordinates":46},"Point",[47,48],-82.32483,29.65163,{"lat":48,"lon":47},[51],{"name":52,"role":32,"phone":53,"phoneExt":18,"email":34},"Erica Elwood, MHA","352-273-6007",{"facility":55,"status":56,"city":57,"state":40,"zip":58,"country":42,"countryCode":43,"cosmosGeoPoint":59,"geoPoint":63,"contacts":64},"UF Health Jacksonville Downtown Emergency Department","RECRUITING","Jacksonville","32209",{"type":45,"coordinates":60},[61,62],-81.65565,30.33218,{"lat":62,"lon":61},[65,69],{"name":66,"role":32,"phone":67,"phoneExt":18,"email":68},"Morgan Henson, MPH","904-244-4234","morgan.henson@jax.ufl.edu",{"name":70,"role":28,"phone":18,"phoneExt":18,"email":18},"Sophia Sheikh, MD",{"facility":72,"status":56,"city":57,"state":40,"zip":73,"country":42,"countryCode":43,"cosmosGeoPoint":74,"geoPoint":76,"contacts":77},"UF Health Jacksonville North Emergency Department","32218",{"type":45,"coordinates":75},[61,62],{"lat":62,"lon":61},[78,79],{"name":66,"role":32,"phone":67,"phoneExt":18,"email":68},{"name":70,"role":28,"phone":18,"phoneExt":18,"email":18},{"type":81,"investigatorFullName":18,"investigatorTitle":18,"investigatorAffiliation":18,"oldNameTitle":18,"oldOrganization":18},"SPONSOR",[83],{"name":84,"class":85},"National Human Genome Research Institute (NHGRI)","NIH","100550516","trial-of-precision-medicine-in-emergency-departments-100550516",false,"NCT06448091","Trial of Precision Medicine in Emergency Departments","TOPMEDs","Inclusion Criteria:\n\n1. Adults 40 years or older presenting to a participating ED\n2. Receipt of a new order\u002Fprescription for a selected PGx medication (Appendix 1), with a duration greater than 7 days, during the current ED visit or within 30 days prior.\n3. Documentation of at least 2 prior ED or urgent care visits within the past 12 months\n\nExclusion Criteria:\n\n1. Prior clinical pharmacogenetic test results within the EHR for genes relevant for this study (Appendix 1).\n2. History of hepatic or renal transplant\n3. History of severe liver disease (stage Child-Pugh C) or renal disease eGFR \\\u003C15 ml\u002Fmin.\n4. Any medical condition that would prohibit the ability to complete the study\n5. Prisoners, wards of the state, or patients being held under the Baker Act or Marchman Act\n6. Life expectancy less than 6 months",true,"ALL","40 Years",{"count":97,"type":98},1200,"ESTIMATED","INTERVENTIONAL",[101],"NA","The objectives of this study are to (1) test the feasibility of the clinical implementation of preemptive pharmacogenetic (PGx) testing in the emergency department (ED) and (2) determine if PGx testing (with appropriate decision support) decreases ED return visits and hospitalizations. We will conduct a randomized, controlled, pragmatic clinical trial assessing both the real-world effectiveness as well as implementation outcomes using a targeted PGx testing panel in several UF Health EDs.",[104],"Pharmacogenomic Drug Interaction","2026-06-08",{"date":107,"type":108},"2026-06-10","ACTUAL",{"date":110,"type":108},"2025-03-18",{"date":112,"type":98},"2029-02-01",{"name":5,"class":6},3]